The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A co-clinical phase II trial of carboplatin and docetaxel as neoadjuvant treatment for triple negative breast cancer with genomic discovery analysis.
 
Foluso Olabisi Ademuyiwa
No Relationships to Disclose
 
Shunqiang Li
No Relationships to Disclose
 
Tracy Skinner
No Relationships to Disclose
 
Jason Hoshower
No Relationships to Disclose
 
Jingqin Luo
No Relationships to Disclose
 
Cynthia X. Ma
Consulting or Advisory Role - Novartis
Research Funding - Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Novartis
 
Katherine N. Weilbaecher
No Relationships to Disclose
 
Michael Naughton
No Relationships to Disclose
 
Leonel Fernando Hernandez-Aya
No Relationships to Disclose
 
Elaine R. Mardis
No Relationships to Disclose
 
Matthew James Ellis
Employment - Bioclassifier
Leadership - Bioclassifier
Stock and Other Ownership Interests - Bioclassifier
Consulting or Advisory Role - AstraZeneca; Celgene; NanoString Technologies; Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Patent on PAM50, which generates royalties on the license to Bioclassifier/Prosigna/Nanostring
Travel, Accommodations, Expenses - AstraZeneca; Pfizer